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ABSTRACT
Resistance to chemotherapy represents a major obstacle to successful treatment. 
The generation of reactive oxygen species (ROS) has been directly linked to the 
cytotoxic effects of several antitumor agents, including Adriamycin (ADR), and 
modulation of the oxidative balance has been implicated in the development and/or 
regulation of resistance to chemotherapeutic drugs. We recently showed that high 
glucose (HG) markedly diminished the cancer cell death induced by anticancer agents 
such as ADR. In the present study we attempted to evaluate the mechanism that 
impaired the cytotoxic effect of ADR in HG. We found that, in colon cancer cells, 
HG attenuated ADR-induced ROS production that consequently diminished ADR-
induced H2AX phosphorylation and micronuclei (MN) formation. Mechanistically, HG 
attenuation of ADR-induced ROS production correlated with increased antioxidant 
response promoted by NRF2 activity. Thus, pharmacologic inhibition of NRF2 pathway 
by brusatol re-established the ADR cytotoxic effect impaired by HG. Together, the data 
provide new insights into chemotherapeutic-resistance mechanisms in HG condition 
dictated by increased NRF2-induced antioxidant response and how they may be 
overcome in order to restore chemosensitivity and ADR-induced cell death.
INTRODUCTION
Chemotherapy can kill the drug-sensitive cancer 
cells, but the drug-resistant cells left behind can cause 
tumor recurrence (or relapse) and even cancer metastasis 
[1]. Development of drug resistance is therefore an 
important factor in anticancer therapeutic failure [2]. Two 
types of resistance occur, that is, intrinsic or acquired. 
Mechanistically, a variety of different systems contribute 
to chemoresistance including tumor heterogeneity, drug-
inactivation, evasion of apoptosis, enhanced DNA repair 
and increased drug efflux [3–5]. The effectiveness of 
traditional cancer chemotherapy is largely based on 
the generation of reactive oxygen species (ROS) and 
consequently on the oxidative stress that exceeds the 
reduction capacity of cancer cells, leading ultimately to 
apoptosis or necrosis [6–8]. Most conventional and also 
non conventional chemotherapeutic agents as well as 
radiotherapeutic agents kill cancer cells by stimulating 
ROS generation [9–12]. Redox resetting usually occurs 
in anticancer drug treatment as a protective response 
from tumor cells to cope with drug-induced stress and 
DNA damage, leading ultimately to drug resistance [13]. 
Thus, alteration in redox balance, and deregulated redox 
signaling are common hallmarks of cancer progression 
and resistance to treatment [14]. ROS balance is typically 
regulated by antioxidant enzymes including catalase, 
superoxide dismutase (SOD) and glutathione S-transferase 
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(GST) which detoxify ROS, reduce ROS-dependent 
apoptosis and attenuate chemotherapeutic cytotoxicity 
[8, 10]. Antioxidant protein expression is regulated 
by the transcription factor nuclear factor erythroid 
2-related factor 2 (NRF2) which is the major regulator 
of the antioxidant response [15]. NRF2 is activated 
during oxidative and electrophilic stress through release 
from its inhibitory Keap1 (Kelch-like ECH-associated 
protein 1) to bind antioxidant responsive elements 
(ARE) in the promoter of target genes including catalase, 
GST, SOD, and NAD(P)H quinone oxidoreductase 1 
(NQO1) [16], promoting their transcription. However, 
noncanonical activation of NRF2 may also occur and is 
mediated by p62-induced KEAP1 degradation through 
autophagy [17] or by the p53 target p21 which up-
regulates the NRF2 signaling pathway by interrupting 
KEAP1/NRF2 interaction and therefore inducing NRF2 
stabilization [18]. Activation of the NRF2-induced 
pathway in cancer has been shown to be critical for 
chemotherapeutic resistance. Among the NRF2 targets, 
catalase overexpression has been shown to protect cancer 
cells from apoptosis induced by DNA-damaging agents 
[19, 20]. Similarly, a role of NQO1 in chemotherapeutic 
resistance has been demonstrated and inhibition of NQO1 
has been shown to suppress cancer cell growth and to 
potentiate cytotoxicity of anticancer agents [21–23]. 
Therefore, targeting NRF2 signaling may be a potentially 
attractive target to combat chemoresistance [15, 16, 24]. 
Among NRF2-targeting agents brusatol, a quassinoid 
extracted from Brucea javanica, that has been shown to 
enhance the efficacy of chemotherapy by inhibiting the 
NRF2-mediated defense mechanism [25, 26].
We have previously reported that attenuation of 
drug-induced cancer cell death occurs when cancer cells 
are switched form low to high glucose (HG) condition and 
are treated with Adiamycin, (ADR), highlighting by several 
mechanisms [27–30]. Since the production of ROS induced 
by the chemotherapeutic drug ADR is considered a major 
trigger for apoptotic cell death [31], in the present study we 
aimed at evaluating whether the reduced chemotherapeutic 
sensitivity promoted by HG in colon cancer cells might 
depend on deregulated ADR-induced ROS generation. To 
this end we evaluated the production of ROS and of the 
antioxidant response induced by ADR under conditions of 
low and high glucose in colon cancer cell lines, in vitro, 
and how it can modify drug-induced cell death.
RESULTS
High glucose (HG) attenuated the ADR-induced 
ROS generation
The ROS levels were first assessed in RKO and 
HCT116 cells treated with ADR in low and HG condition, 
by DCF fluorescence. Results show that ROS levels 
markedly increased when the cells were treated with ADR 
in low glucose (Figure 1, compare lane 2 with lane 1) but 
not when they were treated with ADR in HG (Figure 1, 
compare lane 2 with lane 3). Attenuation of ADR-induced 
ROS in HG was comparable to that obtained by using the 
ROS scavenger NAC in low glucose (Figure 1, compare 
lane 2 with lane 3 and lane 2 with lane 4). Of note, HG per 
se did not modify intracellular ROS levels, indicating that 
it was instead triggering some mechanisms to reduce the 
effect of the drug. These data indicate that HG lowered the 
production of ROS induced by ADR to levels comparable 
to that obtained by NAC inhibition of ROS production by 
ADR in low glucose.
High glucose (HG) reduced ADR-induced DNA 
damage and cell death
Then, we evaluated whether the modulation of 
ROS had an effect on drug-induced DNA damage and 
consequently on cell death. To this aim, γH2AX levels 
and micronuclei (MN) formation were evaluated. H2AX 
phosphorylation in Ser139, generating γH2AX, occurs in 
general in response to double-strand brakes (DSB) and is 
an early sign of replication stalling [32]. We found that 
ADR treatment in low glucose strongly induced γH2AX 
levels while ADR treatment in HG condition failed to do 
so (Figure 2A), suggesting reduction of DNA damage. 
MN are acentric chromosomal fragments or whole 
chromosomes lost during cell division as a result of DNA 
damage and are commonly detected in cells exhibiting 
intrinsic genomic instability or following exposure to 
genotoxic agents [33, 34]. We found that the ADR-induced 
MN formation in low glucose (Figure 2B, compare lane 
2 with lane 1) was significantly reduced in HG condition 
(Figure 2B, compare lane 2 with lane 3). To evaluate the 
role of ROS in MN formation, the ROS scavenger NAC 
was used. The results show that the ADR-induced MN 
formation in low glucose was greatly reduced by NAC 
treatment (Figure 2B, compare lane 2 with lane 4) to the 
levels obtained by ADR in HG (Figure 2B, compare lane 
4 with lane 3), confirming the role of drug-induced ROS 
in DNA damage.
Since drug-induced ROS generation and DNA 
damage are the major trigger for cell death [9–11] the cell 
viability was evaluated by FACS analysis. As shown in 
Figure 2C, ADR treatment markedly increased cell death 
in low glucose (Figure 2C, compare lane 2 with lane 1), but 
this effect was attenuated by HG (Figure 2C, compare lane 
2 with lane 3). In addition, NAC reduced ADR-induced 
cell death in low glucose (Figure 2C, compare lane 4 with 
lane 2) to the levels obtained by ADR in HG (Figure 2C, 
compare lane 4 with lane 3), in agreement with the above 
role of drug-induced ROS in inducing DNA damage. Of 
note, HG alone did not change cell death (Figure 2C), as 
previously shown [27]. Together, these results indicate that 
HG reduced the ADR-induced cell death as a consequence 
of attenuation of ROS production.
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High glucose (HG) increased antioxidant 
response during ADR treatment
We next aimed at evaluating the mechanisms 
involved in ROS modulation by HG, keeping in mind that 
the antioxidant response contributes to chemotherapeutic-
resistance [6, 9, 10, 14]. We found that the levels of 
catalase, a ROS scavenger enzyme [19] (Figure 3A) 
and of NQO1, another antioxidant protein (Figure 3B) 
markedly increased when cells were treated with ADR 
in HG, but not when cells were treated in low glucose 
(Figure 3A and Figure 3B, compare lane 3 with lane 2). 
In addition, greater NRF2 accumulation was achieved in 
cells treated with ADR in HG, compared to the treatment 
in low glucose (Figure 3C, compare lane 2 with lane 1). 
Since the modulation of NRF2 levels does not clearly 
indicate its function, the NRF2 transcriptional activity 
was assessed by the NRF2 ARE-Luc assay. As shown 
in Figure 3D, ARE-Luc activity was greatly increased 
by ADR in HG condition (Figure 3D, compare lane 3 
with lane 2) but only slightly enhanced in low glucose 
condition (Figure 3D, compare lane 1 with lane 2). Next 
we aimed at evaluating the role of NRF2 in modulation of 
the antioxidant response, by its pharmacologic inhibition. 
Among the NRF2-targeting agents, brusatol, a quassinoid 
extracted from Brucea javanica, has been shown to inhibit 
the NRF2-mediated defense mechanism [25]. We found 
that the NQO1 levels (Figure 3B, compare lane 3 with lane 
4) as well as the NRF2 levels (Figure 3C, compare lane 2 
with lane 3) in ADR/HG were greatly reduced by brusatol. 
In agreement, brusatol markedly reduced ADR-induced 
NRF2 ARE-Luc activity in HG condition (Figure 3D, 
compare lane 3 with lane 4). These findings suggest that 
in ADR/HG condition an increased antioxidant response 
occurred, mediated by NRF2 activity.
Inhibition of the antioxidant response rescued 
ADR-induced DNA damage and cell death, 
attenuated by high glucose (HG)
Having established that an increased antioxidant 
response occurred when cells were treated with ADR 
in HG, we aimed at evaluating whether its targeting 
could rescue ADR-induced DNA damage and cell death, 
Figure 1: HG reduces ADR-induced ROS generation. HCT116 and RKO were treated with ADR (2 μg/ml for 6 h) in low or high 
glucose (HG) with or without NAC (10 μM, added 1 h before ADR). Then, the cells were incubated with 10 μM DCFDA and fluorescence 
was determined by flow cytometry. Data shown are the means ± s.d. of n = 3 independent experiments; ANOVA test with Bonferroni 
correction: *p < 0.001.
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Figure 2: HG reduces ADR-induced DNA damage. (A), RKO and HCT116 were treated with ADR (2 μg/ml for 16 h) in low or 
high glucose (HG). Equal amount of total cell extracts was analysed by Western immunoblotting with anti-γH2AX antibody. Representative 
images are shown. Anti-β-actin was used as protein loading control. Densitometric analysis was applied to quantify γH2AX expression/β-
actin ratio and expressed as fold change to Mock (upper panel). Data are presented as the means ± s.d. of n = 4 independent experiments; 
ANOVA test with Bonferroni correction: *p < 0.001. (B), RKO and HCT116 cells were treated with ADR (2 μg/ml) for 1 h with or without 1 
h pretreatment with NAC (10 μM), in low and HG. After treatments, fresh medium was added with 1 μg/ml cytochalasin B for 48 h in order 
to obtain binucleated (BN) cells. Then, cells were stained with Giemsa and observed under a light microscope using high magnification 
(×1000). The results are expressed as total MN on 1000 BN cells (MN‰). Data are presented as the means ± s.d. of n = 3 independent 
experiments; ANOVA test with Bonferroni correction: *p < 0.001. (C), RKO and HCT116 cells were treated with ADR (2 μg/ml) in low and 
HG with or without 1 h pretreatment with NAC (10 μM). After 24 h treatment, cells were fixed and stained with PI for sub-G1 evaluation. 
Data are presented as the means ± s.d. of n = 3 independent experiments. ANOVA test with Bonferroni correction: *p < 0.001.
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Figure 3: Increased antioxidant response during ADR treatment in HG condition. (A), RKO and HCT116 cells were treated 
with ADR (2 μg/ml for 16 h) in low glucose or HG. Equal amount of total cell extracts was analysed by Western immunoblotting with anti-
catalase antibody. Representative images are shown. Anti-β-actin was used as protein loading control. Densitometric analysis was applied 
to quantify catalase expression/β-actin ratio and expressed as fold change to Mock, fixing the control to 1. (B), RKO and HCT116 cells were 
pre-treated with brusatol (100 nM for 4 h) and then treated with ADR (2 μg/ml for 16 h) in low glucose or HG. Equal amount of total cell 
extracts was analysed by Western immunoblotting with anti-NQO1 antibody. Representative images are shown. Anti-β-actin was used as 
protein loading control. Densitometric analysis was applied to quantify NQO1 expression/β-actin ratio is expressed and expressed as fold 
change to Mock, fixing the control to 1. (C), RKO cells were pre-treated with brusatol (100 nM for 4 h) and then treated with ADR (2 μg/
ml for 16 h) in low glucose or HG. Equal amount of total cell extracts was analysed by Western immunoblotting with anti-NRF2 antibody. 
Representative images are shown (upper panel). Anti-β-actin was used as protein loading control. Densitometric analysis was applied to 
quantify NRF2 expression/β-actin ratio and expressed as fold change to Mock, fixing the control to 1. (D), RKO and HCT116 cells were 
transfected with the NRF2 ARE-Luc vector and treated as in (C); then relative luciferase activity was measured. The results of ARE-luc 
activity are shown as the means ± s.d. of n = 3 independent experiments. ANOVA test with Bonferroni correction: *p < 0.001.
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attenuated by HG. We found that the lack of H2AX 
phosphorylation in ADR/HG was counteracted by brusatol 
(Figure 4A, compare lane 3 with lane 4), taking back the 
γH2AX levels to those achieved by ADR in low glucose 
(Figure 4A, compare lane 4 with lane 2), suggesting re-
establishment of ADR-induced DNA damage in HG. In 
agreement, cell viability analysis shows that the attenuation 
of ADR-induced cell death in HG (Figure 4B, compare lane 
2 with lane 3), was counteracted by brusatol (Figure 4B, 
compare lane 3 with lane 4), taking back the cell death 
levels to those achieved by ADR in low glucose (Figure 4B, 
compare lane 4 with lane 2), suggesting re-establishment of 
ADR-induced cell death in HG. These data indicate that 
targeting the antioxidant response in HG could restore 
DNA damage and cell death in response to ADR.
DISCUSSION
A number of medical conditions can increase 
blood glucose concentration (hyperglycemia), including 
diabetes mellitus (DM), obesity, pancreatitis, chronic 
stress, and cancer [35, 36], and hyperglycemia has been 
shown to attenuate tumor therapeutic response and to 
confer resistance to chemotherapy-induced cell death [37, 
38]. At molecular level, HG modulates various signaling 
pathways that control cancer cell proliferation, migration 
and recurrence [39, 40], as well as apoptosis [27, 39–43]. 
In our previous studies we showed that HG reduces ADR-
induced cell death. Mechanistically, culturing cancer 
cells with HG or sera from diabetic patients reduces the 
drug-induced apoptotic activity of p53 [27, 28]. In this 
metabolic condition p53 changes its affinity for target 
promoters preferring for instance to transcribe damage-
regulated autophagy modulato (DRAM) that induces 
autophagy, instead of transcribing p53 upregulated 
modulator of apoptosis (PUMA), inducing a pro-
survival autophagy whose inhibition can re-establish 
drug cytotoxicity [29]. The HG condition inhibits 
also the drug-induced c-jun-N-terminal kinase (JNK) 
pathway that can be rescued by ZnCl2 supplementation 
that counteracts the glycolytic pro-survival pathway 
restoring cancer cell chemosensitivity [30]. In vivo 
study confirmed that ADR treatment does not reduce the 
growth of a xenograft tumor in diabetic mice, as it does in 
normal glycemic control mice [29]. These findings are in 
agreement with preclinical studies where hyperglycemia 
is associated with attenuation of the antiproliferative 
effect of chemotherapy [44], underlining a multifaceted 
influence of hyperglycemia in the regulation of cancer 
cell chemosensitivity.
Most conventional and also non conventional 
chemotherapeutic agents as well as radiotherapeutic 
agents kill cancer cells by stimulating ROS generation 
that promotes DNA damage [6, 9–12, 14]. In agreement, 
here we found that ADR-induced ROS increased DNA 
damage ultimately inducing cell death. However, when 
ADR-induced ROS production was attenuated by 
HG, also H2AX phosphorylation and MN formation 
were reduced, along with cell death, linking the ROS 
production with DNA damage and cell death and 
therefore with the cell ability to cope with oxidative stress 
in order to survive. Therefore, we hypothesized a role 
for the antioxidant response to explain ROS modulation 
in ADR/HG condition, corroborated by the fact that 
persistent oxidative stress induces adaptive responses 
including antioxidant up-regulation conferring resistance 
to apoptosis [7]. Thus, we found increased catalase and 
NQO1 levels in ADR/HG, suggesting indeed increased 
antioxidant response. Catalase overexpression has been 
shown to protect cancer cells from apoptosis induced 
by DNA-damaging agents, rendering catalase a future 
therapeutic target [19, 20]. Similarly, a role of NQO1 in 
cancer chemotherapy has been demonstrated by several 
groups and inhibition of NQO1 has been shown to 
suppress cancer cell growth and to potentiate cytotoxicity 
of anticancer agents [21–23] and its downregulation may 
restore cancer cell sensitivity to chemotherapeutic agents 
as an attractive strategy for treating cancers. Although the 
antioxidant response can be seen as an obstacle to the drug 
cytotoxic effect, one limitation of our study is that we 
used only one drug to show the antioxidant mechanism in 
HG condition. It would be interesting to test if also other 
drugs that stimulate ROS generation as a mechanism of 
cell death might undergo increased antioxidant response 
in HG. Therefore, more experiments with different drugs 
should be performed in order to generalize these findings 
and make them useful for clinical applications. Another 
point that needs to be further explored is if high glucose 
could interfere with uptake of ADR or be direct on 
adriamycin metabolism by impairing the effectiveness of 
the chemotherapy itself.
Antioxidant proteins expression is regulated by 
NRF2 whose activation provides a growth advantage 
for cancer cells, protects against oxidative stress, and 
contributes to chemotherapeutic-resistance [45, 46]. 
Under unstressed condition, NRF2 forms a complex with 
Keap1, leading to protein degradation. Upon exposure 
to different stressors, including ROS, toxic agents and 
carcinogens, NRF2 is released from Keap1, translocates 
to the nucleus, binds AREs in antioxidant gene promoters 
and up-regulates expression of target genes [47]. However, 
noncanonical activation of NRF2 may exists mediated, for 
instance, by p53 target p21 that, by interrupting KEAP1/
NRF2 interaction, induces NRF2 accumulation and up-
regulates the NRF2 signaling pathway [18]. Here, we 
found that ADR treatment in HG condition increased the 
NRF2 activity and the expression of NRF2 target genes 
catalase and NQO1, thus contributing to reduce the drug 
cytotoxic effect. In the attempt to explain the mechanisms 
of NRF2 up-regulation, we can argue that p53 may play 
a role. Thus, we have previously reported that HG, by 
modulating p53 post-translational modifications and 
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therefore p53 transactivation function, reduces the p53-
induced apoptotic gene transcription while increases the 
transcription of autophagy gene such as DRAM or p21 
(data not shown). It could be likely that p21, in this ADR/
HG setting, could activate NRF2, although further studies 
are needed to explain this link.
Having assessed that an increased antioxidant 
response occurred in ADR/HG, we aimed at evaluating 
whether its manipulation could rescue ADR-induced 
DNA damage and cell death, attenuated by HG. NRF2-
targeting agents can be used to overcome antioxidant 
response-dependent chemotherapeutic-resistance [24] 
and brusatol, a quassinoid extracted from Brucea javanica, 
has been shown to enhance the efficacy of chemotherapy 
by inhibiting the NRF2-mediated defense mechanism 
[25, 26]. Brusatol may abrogate gemcitabine-induced 
NRF2 activation in pancreatic cancer cells to restore 
chemosensitivity of cancer cells [48]; may enhance the 
radiosensitivity of lung cancer cells by promoting ROS 
production and enhancing DNA damage [49]; and may 
inhibit cancer cell growth and induce apoptosis via JNK/
p38 MAPK/NF-κb/Stat3/Bcl-2 [50]. In line with these 
findings, we show that brusatol re-sensitized cancer cells 
to drug cytotoxic activity inhibited by HG and inhibited 
NRF2-dependent activity.
In summary, the present study shows that HG 
reduced ADR-induced cell death by impairment of ROS 
production and increased antioxidant response through 
induction of the NRF2 activity. Therefore, this study 
may suggest that targeting the antioxidant response 
might contribute to restore chemotherapeutic sensitivity 
and ADR-induced cell death, inhibited by HG. In 
addition, once this mechanism is validated by using 
different anticancer agents, the concept to highlight 
the antioxidant response could be exploited also for 
predictive and prognostic purposes. To this aim, the new 
technological method of liquid biopsy could be of help 
in measuring for instance circulating tumor DNA and 
micro-RNA modified by HG and in response to drugs 
[51–53].
Figure 4: Brusatol restores ADR-induced DNA damage and cell death impaired by HG. (A), RKO and HCT116 cells were 
pre-treatred with brusatol (100 nM for 4 h) prior to adding ADR (2 μg/ml for 16 h), in low glucose and in HG. Equal amount of total cell 
extracts was analysed by Western immunoblotting with anti-γH2AX antibody. Representative images are shown. Anti-β-actin was used as 
protein loading control. Densitometric analysis was applied to quantify NRF2 expression/β-actin ratio. (B), RKO and HCT116 cells were 
treated as in (A) and 24 h after treatments, the percentage of dead cells was scored by Trypan blue staining. Data shown are the means ± s.d. 
of n = 3 independent experiments. ANOVA test with Bonferroni correction: *p < 0.001. 
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MATERIALS AND METHODS
Cell culture and reagents
Mycoplasma negative human RKO and HCT116 
colon cancer cell lines (ATCC) were routinely cultured 
in Dulbecco modified Eagle’s medium (DMEM) (Life 
Technology-Invitrogen, Carlsbad, CA, USA) containing 
1 g/L D-glucose (considered low glucose) supplemented 
with 10% heat-inactivated foetal bovine serum (FBS) 
(GIBCO-BRL, Grand Island, NY, USA) plus 100 units/
ml penicillin/streptomycin and glutamine in 5% CO2 
humidified incubator at 37°C. For the experiments in 
high glucose (HG), cells, routinely cultured in medium 
containing 1 g/L D-glucose, were washed in PBS, 
and then replaced with culture medium containing 4.5 
g/L D-glucose (high glucose – HG) plus 2% FBS, as 
previously reported [27, 39, 40]. Control experiments in 
low glucose were also performed in 2% FBS.
The chemotherapeutic drugs Doxorubicin (herein 
referred as Adriamycin, ADR) (Sigma-Aldrich) was added 
to the culture media at 2 μg/ml for the indicated times. 
The ADR amount used in this study, that is 2 μg/ml, was 
previously reported by us to induce apoptosis in RKO and 
HCT116 cells [27]. The ROS inhibitor N-acetyl-L-cysteine 
(NAC) (Sigma-Aldrich, St Louis. MO, USA) was used at 
10 μM; antioxidant response inhibitor Brusatol (Sigma-
Aldrich) was used at 100 nM; Cytochalasin B (Sigma, St 
Louis, MO, USA) was used at 1 μg/ml.
Measurement of intracellular reactive oxygen 
species (ROS) production
To measure reactive oxygen species (ROS) 
production, we used 2′,7′-dichlorofluorescein diacetate 
(DCFDA; Sigma–Aldrich), a highly fluorescent compound 
that after diffusion into the cell, is oxidized by ROS into 
2′,7′-dichlorofluorescein (DCF), and can be detected by 
fluorescence spectroscopy, as reported [54]. Briefly, cells 
were plated in duplicate on six-well culture plates. The 
day after plating, cells were washed in PBS before adding 
HG culture media and low glucose media for the controls, 
for 24 h prior to adding the indicated treatments (ADR - 2 
μg/ml - for 6 h in the presence or absence of NAC - 10 μM 
- added 1 h before ADR). Following treatment, cells were 
washed with PBS and incubated with 10 μM DCFDA, 
for 15 min at 37°C. Cell pellets were then collected and 
analyzed in the FL-1 channel of a FACScalibur flow 
cytometer (Becton–Dickinson). DCF fluorescence was 
determined using 5 × 105 cells/ml and values expressed as 
mean DCF fluorescence per cell population.
Cell viability
To measure cell viability we used Trypan blues 
staining, as previously reported [27]. Briefly, equal 
numbers of cells were plated in duplicate in 60 mm Petri 
dishes. The day after plating, cells were washed in PBS 
before adding HG culture media and low glucose media 
for the controls, for 24 h before dispensing the indicated 
treatments. Cell viability was determined by Trypan 
blue staining of both floating and adherent cells and 
was measured by direct counting blue/white cells with a 
haemocytometer. The percentage of dead cell (blue/total) 
was calculated from 200 cells per well in triplicate.
Cell death/PI staining
Cell death was quantified by Fluorescence Activated 
Cell Sorting (FACS) analysis, staining cells with the 
nonvital dye propidium iodide (PI) (Immunological 
Sciences, Rome, Italy), following the manufacturer’s 
instruction. Briefly, adherent cells were tripsinized and 
then collected along with floating cells by centrifugation; 
then, cell pellets were fixed in 80% ethanol and stained 
in a PBS solution containing propidium iodide (PI) (62.5 
mg/ml; Sigma-Aldrich) and RNase A Q10 (1.125 mg/
ml; Sigma-Aldrich), as reported [55]. Stained samples 
were then analyzed with a FACScan instrument (Becton 
Dickinson Europe Holdings SAS - Le Pont De Claix, 
France) and the percentage of cells in sub G1 compartment 
was calculated using ModFit LT software (Becton 
Dickinson). Approximately 30000 events were acquired 
and gated using forward scatter and side scatter to exclude 
cell debris.
Analysis of micronuclei (MN) by Cytokinesis-
block micronucleus (CBMN) assay
Analysis of MN was assessed by Cytokinesis-block 
micronucleus (CBMN) assay [56]. Briefly, 3 × 105 cells 
were seeded on coverslips in 60 mm Petri dish. The day 
after plating, cells were washed in PBS before adding HG 
culture media and low glucose media for the controls, for 
24 h prior to adding a pulse of ADR (2 μg/ml) for 1 h, 
with or without NAC (10 μM, added 1 h before ADR). 
Following treatment, cells were replaced with fresh 
medium containing 1 μg/ml cytochalasin B, for 48 h, in 
order to obtain binucleated (BN) cells. Cells were then 
fixed in cold methanol for 10 min, air dried and stained 
with Giemsa. The coverslips were mounted on slides 
that were observed under a light microscope using high 
magnification (×1000). For each experimental point, at 
least 1000 BN cells were analysed, cells with one or more 
MN recorded and results expressed as total MN on 1000 
BN cells (MN‰).
Western blot analysis
Total cell extracts were prepared by incubation in 
lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 
mM EDTA, pH 8.0, 150 mM KCl, 1 mM dithiothreitol, 
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1% Nonidet P-40) and a mix of protease and phosphatase 
inhibitors (Roche, Indianapolis, IN, USA) on ice for 30 
min. Cell debris was removed by centrifugation (15000 × g 
for 20 min) and supernatant collected. Protein 
concentration was determined using BCA Protein Assay kit 
(BioRad, Hercules, CA, USA). Samples were denatured in 
SDS sample buffer. Total cell extracts (10–40 μg total cell 
lysate/lane) were resolved by 9–18% SDS polyacrylamide 
gel electrophoresis and transferred to polyvinylidene 
difluoride (PVDF) (Merck Millipore, Billerica, MA, 
USA) or nitrocellulose (BioRad) membranes by using 
the MiniPROTEAN 3 apparatus (Bio-Rad). Unspecific 
binding sites were blocked by incubating membranes 
for 1 h in 0.05% Tween-20 (v/v in TBS) supplemented 
with 5% non-fat powdered milk or bovine serum albumin 
(BSA) (SIGMA-Aldrich), followed by overnight (o/n) 
incubation with the following primary antibodies: mouse 
monoclonal anti-phospho-Histone H2AX (Ser139) 
(Millipore), rabbit monoclonal anti-NRF2 (Abcam, 
ab62352), mouse monoclonal anti-catalase (H-9) (Santa 
Cruz Biotechnology, sc-271803), mouse monoclonal anti-
NQO1 (A180) (Thermo-Scientific). Primary antibodies 
were detected with appropriate anti-immunoglobulin-G-
horseradish peroxidase secondary antibodies (BioRad). 
Enzymatic signals were visualized by chemiluminescence 
(ECL Detection system, Amersham GE Healthcare, 
Milan, Italy), according to the manufacturer’s protocol. 
Equal lane loading was monitored by probing membranes 
with antibodies specific for mouse monoclonal β-actin 
(Calbiochem, San Diego, CA, USA). Densitometry 
was performed with ImageJ software and relative band 
intensity normalized to β-actin and quantified with respect 
to controls set to 1.0.
NRF2 ARE-Luc activity
Sub-confluent cells were plated on white clear 
bottom 96-multiwell culture plates. The day after, cells 
were transfected with the NRF2 ARE-Luc reporter 
vector (ARE Reporter kit, antioxidant pathway, BPS 
Bioscience), using Lipofectamine Plus reagent according 
to the manufacturer’s instructions (Invitrogen, Carlsbad, 
CA, USA). Sixteen hours after transfection, cells were 
washed in PBS before adding HG culture media, and low 
glucose media for the controls, pre-treated with brusatol 
(100 nM for 4 h) followed by the addition of ADR (2 μg/
ml for 16 h). Luciferase activity was assayed on whole-
cell extracts, according to the manufacturer’s instructions.
Statistical analysis
Each experiment, was performed at least three times. 
Results are reported as the mean ± standard deviation 
(s.d.) or as fold change to mock or as protein expression/β-
actin ratio expressed as numbers underneath images fixing 
the control to 1. Statistical significance was determined 
using one-way ANOVA analysis for three or more sample 
comparisons using GraphPad Prism software (San Diego, 
CA, USA), with post hoc Bonferroni correction. A value 
of p < 0.05 was considered statistically significant.
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